stock decline

Stellantis faces securities fraud class action after stock plummeted 23.69% following disclosure of €22 billion in charges and business reset amid misrepresented electrification strategy.

ImmunityBio faces securities fraud lawsuit after executive allegedly misrepresented ANKTIVA cancer drug capabilities; stock fell 21% following FDA Warning Letter.

Fermi (FRMI) plummets 19% after CEO and CFO departures, headquarters relocation to Dallas, and concerns over Project Matador tenant securing.

Class action lawsuit filed against $SLNO for alleged misstatements about diazoxide choline safety and efficacy. Lead plaintiff deadline: May 5, 2026.

American Airlines rejects United merger, citing antitrust concerns. $AAL shares fall 5% to $12.24 but maintain Buy rating with $16.10 target.

Corcept Therapeutics faces class action lawsuit alleging investor deception over failed relacorilant drug trial. Stock plunged 50.4% after FDA rejection.

$ASTS stock drops 14% after BlueBird 7 satellite placed in lower-than-planned orbit. Company expects insurance recovery and maintains 2026 launch targets.

$LCID plunges 67% amid persistent losses, delayed mass-market models. Fresh funding from Uber and Saudi PIF fails to restore investor confidence.

Disc Medicine ($IRON) shares fell 22% after FDA rejected its bitopertin drug application, prompting class action investigation into securities claims.

Apollo Global Management faces class action lawsuit over undisclosed Epstein connections. Stock plummeted 15%, erasing $12B in market value following February investigative reports.

Navan faces class action lawsuit alleging IPO prospectus omitted material facts about 39% jump in sales and marketing expenses. Stock has crashed 63% since October IPO.

$DNOW shares crashed 19.1% after disappointing Q4 results. The Rosen Law Firm investigates potential securities violations on behalf of affected shareholders.

Fisher Funds Management increased MercadoLibre stake to $61.33M despite 11.6% annual decline, signaling confidence in platform's 45% revenue growth and 78M users.

Netflix beat Q1 earnings expectations significantly but fell 11.8% Friday due to modest Q2 guidance and co-founder Reed Hastings' board exit announcement.

Rectitude Holdings stock fell 8.76% to $1.58 Friday despite securing S$10M in green energy contracts and launching rebranding initiative targeting Singapore SMEs.

Aquestive Therapeutics faces securities lawsuit after FDA Anaphylm deficiency notice triggers 37% stock decline from $6.21 to $3.91 on January 9, 2026.

Teleflex shares fell 13% after CEO Liam Kelly's sudden departure. Portnoy Law Firm launches securities fraud investigation citing leadership concerns.

Stellantis shareholders can file claims by June 8, 2026, in lawsuit alleging false earnings statements and concealed EV adoption risks that triggered stock collapse.

Medpace faces class action suit alleging false guidance on cancellation rates. Stock plunged 15.9% after Q4 2025 miss, triggering investor claims.

Inspira Technologies stock fell 5.96% after-hours despite announcing AME system deployment at U.S. defense customer, raising questions about investor confidence in micro-cap biotech companies.